Family health history (FHH) is a simple and cost-effective clinical tool widely used by genetic professionals. Although the value of FHH for assessing personal and familial health and reproductive risk within a prenatal population has been demonstrated in past studies, its utility within a genetic carrier screening population has not been evaluated. The purpose of this study was to examine the utility of FHH as a clinical screening tool and explore the general outcomes of full FHH evaluations within an expanded carrier screening (ECS) population. A retrospective chart review was conducted for 500 consults, which included 3-generation pedigrees, using data from the genetic testing company Recombine.
Introduction
Family health history (FHH) is an integral part of genetic counseling consultations.
Collecting FHH in the form of a pedigree often serves as the initial step for a genetic evaluation (Bennett, 2012) . The pedigree provides a graphic representation of medical-family information and biological relationships through standardized nomenclature established by the Pedigree Standardization Task Force of the National Society of Genetic Counselors (Bennett et al., 1995; Bennett et al., 2008) . This allows for an easy and consistent method of recording and interpreting family health information. The family pedigree has long been recognized as a cost-effective risk assessment tool (Bennett, 2012) . It can be used to identify at-risk individuals, establish patterns of inheritance, calculate disease risks, and distinguish genetic contributions from other risk factors (2012) . One of its particular advantages is assisting in risk assessment for conditions without a known molecular cause or distinct Mendelian inheritance pattern (Brenda J Wilson et al., 2009) The scope of a FHH evaluation is often dependent on the practice setting and patient population (ACOG, 2011) . Each type of evaluation serves its own purpose and offers its own advantages. Directed family history evaluations utilize targeted questions for the purpose of assessing disease-risk; these types of directed evaluations are typically used in specialties such as cancer genetics, neurogenetics, and cardiovascular genetics to capture FHH information that is relevant to the condition being assessed (Blankstein & Foody, 2014; Lu et al., 2014; Rubinstein et al., 2011) . Detailed family history evaluations tend to be broader in scope and are more frequently used in preconception and prenatal care (Farahi & Zolotor, 2013) . A number of professional health organizations, including the Centers for Disease Control and Prevention, U.S. Office of the Surgeon General, American Heart Association, American College of Obstetrics and Gynecology, and American Society of Clinical Oncology, endorse the use of thorough FHH as a risk assessment tool given its many benefits (ACOG, 2011; Lu et al., 2014; Tarini & McInerney, 2013; Wu et al., 2015) .
Besides its effectiveness as a risk assessment tool, the utility of FHH as a clinical tool is evident by the array of other functions it serves. It is useful for making a diagnosis, guiding testing strategies, determining reproductive options, and informing decisions on medical management and surveillance (Bennett, 2012) . Collecting FHH also presents opportunities for rapport building, patient education, and exploration of the patient's understanding of the condition or disease of interest (2012) .
There are significant systemic, clinician, and patient-barriers to FHH that hinder its application in clinical practice (Wu et al., 2015) . Systemic barriers include limited resources, including the time and availability of clinical personnel to obtain a thorough family history (2015) . Clinician barriers include the availability of licensed and/or certified genetic professionals with the knowledge and skills to synthesize and interpret family history data for risk stratification (2015) . Patient barriers pertain to the inherent limitations of patientreported information (2015) . A systematic review of the role of family history in risk assessment conducted by Wilson et al. found that the absence of disease in relatives is more often correctly reported than the presence of disease (Brenda J Wilson et al., 2009 ). This shows that patient-reported family history data has the potential to be inaccurate or incorrect.
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Inadequate knowledge about FHH presents an additional barrier in the medically underserved population (Kaphingst et al., 2012) .
FHH can be made more valuable when used in conjunction with genetic testing; FHH provides context for the interpretation of genetic testing results, and risk factors identified through FHH evaluation may prompt consideration of more extensive genetic evaluation and/or testing (Bennett, 2012) . The type of genetic evaluation or testing is often specific to the practice setting.
In reproductive medicine, population-based carrier screening is an integral part of genetic testing and is gaining more widespread use as a screening tool (Yao & Goetzinger, 2016) . Historically, the initial aims of genetic carrier screening focused on identifying carriers to prevent disease occurrence and reduce disease frequency in successive generations (Khoury, McCabe, & McCabe, 2003) . In the 1970's, carrier screening focused on identifying carriers of Tay-Sachs disease within the Ashkenazi Jewish population (Beaudet, 2015) . Due to historical and social factors that limited potential reproductive partners, there was a high incidence of Tay-Sachs within this population (Gross, Pletcher, & Monaghan, 2008) . With the rapid progression of disease-causing genes being identified in other specific populations, ethnicity-based carrier screening panels were expanded to include additional diseases, such as β-thalassemia, sickle cell anemia, and cystic fibrosis (Beaudet, 2015) . By the 2010's, many companies began to offer 'universal carrier screening,' as opposed to ethnicity-based screening for only the at-risk populations (2015) . Screening panels went from testing more than 100 genes using SNP-microarray to applying next-generation sequencing to 437 target genes (2015) . Genetic carrier screening has evolved to encompass autosomal recessive and xlinked disease causing genetic variants (2015) . With the increasing awareness among genetic Katherine Dao and Julia Russo 6/34 carrier screening, the American College of Obstetricians and Gynecologists has endorsed the use of universal carrier screening in the prenatal and preconception setting (Romero, Rink, Biggio, & Saller, 2017) . The recent modification was brought about by the growing uncertainty of a patient's entire ethnicity or background (2017). As healthcare providers and professional organizations push toward universal testing, the need for patient education about the testing received, and risk assessment of the testing results, will increase.
In the preconception and prenatal care setting, genetic carrier screening is often a standard recommendation and is an essential component of predicting risk for inherited genetic conditions (Edwards et al., 2015) . In this setting, genetic carrier screening is typically used in conjunction with FHH to assess an individual's personal and reproductive risk (Farahi & Zolotor, 2013; Yao & Goetzinger, 2016) . The aim of genetic carrier screening is to identify individuals who carry a disease-causing variant that places them at an increased risk for having offspring affected with that condition (Beaudet, 2015) . This risk is particularly significant if the individual's partner is found to be a carrier of the same condition (2015).
Genetic carrier screening enables at-risk couples to be informed of the genetic risks to their offspring and of the reproductive options available to them (Borry et al., 2011) . Genetic carrier screening also provides couples with the opportunity to actively engage in managing their reproductive risks through preconception planning and the use of in vitro fertilization with pre-implantation genetic diagnosis (IVF with PGD) (Edwards et al., 2015) . Through IVF with PGD, high-risk couples have the option to screen for specific genetic conditions prior to transfer of the embryo, greatly reducing their risk of an affected offspring (Antonios, 2012) . Genetic carrier screening also allows for early detection of potentially affected offspring, which may assist in the development of specific management protocols and lead to greater preparedness within families (Ross, Ross, Saal, David, & Anderson, 2013 (Tarini & McInerney, 2013) . The purpose of this study was to examine the general outcomes of full family history evaluations in the context of post-expanded carrier screening genetic counseling sessions. Further goals of this study were to describe the type of information that can be elicited from a FHH evaluation and to evaluate the clinical utility of the information elicited.
Materials and Methods
This study is a retrospective chart review using Recombine's patient database.
Recombine is a genetic testing company that provides expanded carrier screening (CarrierMap). The CarrierMap panel assesses an individual's carrier status for approximately 300 autosomal recessive and x-linked conditions (Appendix A). A randomly selected sample of consults from February 1, 2016 to February 29, 2016 was screened for eligibility into the study. A total of 500 consults meeting the inclusion criteria were obtained. The inclusion criteria included consults in which an individual or a couple received CarrierMap testing, and subsequently consented to a full family history evaluation. For the purpose of this study, a full family history evaluation was defined as a three-generation pedigree in which family members were assessed for intellectual disabilities, learning disabilities, birth defects, blindness, deafness, muscle or skeletal disorders, blood disorders, infant deaths, infertility, recurrent pregnancy loss, consanguinity, and known genetic conditions. The consults were conducted by twenty-one licensed and/or certified genetic counselors with varying years of experience. Data was extracted from the consult letters, and coding was specified for the following variables: consult ID, genetic counselor conducting consult, couple or individual consult, reported gender, date of birth, ethnicity of each individual, indication for testing, carrier screening results, additional follow-up testing based on the carrier screening results, FHH findings such as those requiring recommendations for further follow-up or general risk counseling, and known genetic conditions in the family. For the analysis, FHH findings were assigned to one of two categories: requiring further follow-up, or requiring general risk counseling, which could include risk assessment and/or patient education. General risk counseling was defined as any discussion on reproductive or recurrence risk based on family history and available empiric data. Patient education does not generally include personalized risk information, and may be a part of the general risk counseling process, depending on the patient's knowledge and understanding of the condition being discussed. When a patient received education, information was discussed about the reported finding or condition, including clinical features and patterns of inheritance. Data was de-identified, and no identifiable information was stored. Because the data included private health information, it was maintained in a password-protected database. Once data extraction was completed, the original spreadsheet containing the health privacy information was destroyed.
Initial statistical analysis was performed by a statistician at Sarah Lawrence College, using statistical software, SPSS. Additionally, an independent data analyst was consulted in regards to the confidence interval calculations. Excel was used to calculate the frequency and confidence interval based on the sample size and observed sample proportion. A two-way frequency table analysis assessed the number of consults in which expanded carrier screening yielded positive or negative results with positive or negative FHH findings. The data was also analyzed for the number of consults that received a referral or recommendation for further follow-up based on the reported family history information and the types of follow-up recommendations made. Further analysis was conducted to determine the topics involved during general risk counseling. Discussion topics included known genetic disorders, psychiatric disorders, and various multifactorial conditions, among others.
Results
Consults were screened based on the established inclusion criteria. Eight hundred and sixteen consults were reviewed, of which 316 (38.7%) consults did not meet the inclusion criteria. A total of 500 consults were used in the final analysis. Consults that were excluded from the data set were those that received testing other than the CarrierMap screening panel through Recombine or declined a full family history evaluation. The consults analyzed consisted of 206 (41.2%) couple consults and 294 (58.8%) individual consults ( Table 1) . The sample population was composed of 482 females and 222 males. Genetic carrier screening indications included: IVF using sperm or egg donor, frozen embryo transfer, infertility evaluation, egg donor screening, egg cryopreservation, and reproductive purposes not otherwise specified (Table 2) . Of the 500 total consults, 310 (62.0%) were consults in which the individual or at least one partner of a couple was identified to be a carrier for at least one genetic condition, and 190 (38.0%) were consults for individuals or couples who did not have a positive result on the CarrierMap screening panel (Table 3) . Within the 310 consults with positive carrier screening, 211 (68.0%) also had family history indications warranting further follow-up, general risk counseling, or both (Table 4) .
Within the 190 consults that received negative results on expanded carrier screening, 117 (61.6%) had indications warranting further follow-up, general risk counseling, or both (Table   4) . Consults yielded between one and four types of recommendations for follow-up evaluation ( Table 5 ). The 95% confidence interval for the proportion of consults to produce any type of follow-up evaluation is 44.4% ± 4.4%, or 40.0% to 48.8%. One hundred fiftytwo consults (30.4%) had only one indication to warrant further follow-up. The 95% confidence interval for consults with only one indication is 30.4% ± 4.0%, or 26.4% to 34.4%. Only two consults in the sample, which make up 0.4% of all consults, had a maximum number of four follow-up indications. The 95% confidence interval for consults that had four indications is 0.4% ± 0.6%, which is not significant by statistical standards for the lower limit. Based on family history alone, an overall number of 222 (44.4%) consults had a family history finding that warranted further follow-up, and received either a referral or recommendation for additional evaluation (Table 6 ). The confidence interval for the proportion of consults that had at least one finding to warrant further discussion of reproductive or health risk was 46.6% ± 4.4%, or 42.2% to 51.0% (Table 9 ). Approximately 33.4% (±4.1%) and 10.2% (± 2.7%) of all consults had one and two indications, respectively, within the family history that warranted additional counseling and education. Of the consults that did receive general risk counseling (n=233), a large proportion belonged to those with only one finding in the family history, which was estimated to be 71.7% with a confidence interval of 5.8%, or 65.9% to 77.5% (Table 10) . With regards to topics that were elicited during the evaluation, autoimmune disorders and psychiatric conditions emerged as the top two categories at 16.8% and 10.0%, respectively (Table 11 ). The confidence interval for autoimmune disorders and psychiatric conditions were 3.3% and 2.6%, respectively. Autism spectrum disorders alone accounted for 1.4% of consults with a confidence interval of 1.0%, which also was the lowest incidence category observed. general risk counseling (Figure 1 ). Of the 500 total, 127 (25.4%) consults had family history indications for both further follow-up and general risk counseling.
Discussion
The Without a family history evaluation, close to one-fifth (23.4%) of the 500 total consults with familial findings that affected the individual or couple's reproductive or personal health risk would have been missed. This frequency is comparable to that of previously conducted studies which looked at the frequency of family history findings in patients without previously identified genetic concerns. A study by Hafen et al. reviewed family history data for 700 women and found that a total of 28.4% had some sort of family history finding (Hafen et al., 2009) . Of the 28.4% of women with family history findings, about 19.1% had a family history "positive" for birth defect or genetic condition with a minimal/low risk of recurrence, in which additional evaluation/genetic testing during pregnancy was not indicated, while about 9.3% had family histories "significant" for birth defect or genetic condition with an increased risk of recurrence, in which additional evaluation/genetic testing during the pregnancy was indicated. Additional studies looking at women who were referred for amniocentesis found the frequency of significant family history findings to be around 10 to 43% (Cohn et al., 1999; Holzgreve et al., 1983; Langer and Kudart, 1990; Meschede et al., 2000; Rubin et al., 1983) . The frequency of 23.4% ascertained in this study falls within with the range observed in these previously conducted studies and is lower than that of Hafen's study. The differences in the frequencies can be accounted for by the parameters used to determine and categorize the significance of family history data as well as the demographics of the population sampled. These factors limit the extent to which the findings can be generalizable to other prenatal patient populations since this study's cohort was ascertained specifically from a population for which carrier screening was indicated.
FHH, when considered alone, yielded clinically actionable data which prompted follow-up recommendations in 222 consults (44.4% of the total consults). This included recommendations for follow-up with cancer genetic counseling, cardiology and cardiovascular genetics, neurogenetics, a general genetics evaluation, a prenatal ultrasound, an infertility work-up, and other subspecialties including ophthalmology, audiology, dermatology, and endocrinology. The results of the study indicated that family history evaluations were most likely to identify to cancer indications, which produced follow-up recommendations for cancer genetic counseling in over a quarter of the total number of consults. The second highest number of recommendations made was to a general genetics provider; this composed over 10% of total consults. An overwhelming majority of these genetic evaluation recommendations were due to a diagnosis of an autism spectrum disorder (ASD) within the family. It was observed that the option of an ASD evaluation to identify the underlying cause was dependent on the discretion of the genetic counselor conducting the session, as some counselors were more likely to refer, irrespective of the degree of relation to the individual or couple.
Oftentimes, a family history evaluation led to multiple follow-up recommendations; it was observed that each consult yielded follow-up recommendations for between one to four different types of evaluations. Almost one-third of all consults had one recommendation for an additional evaluation. Four recommendations were warranted in two of the 500 consults (less than half of one percent). With only two observed in a sample size of 500, consults with four different recommendations yielded an insignificant lower confidence bound.
Some consults had family-history-based findings that elicited discussions on general risk counseling. For these particular consults, genetic counselors provided risk assessment and patient education as needed. Topics that came up per patient report included known genetic disorders within the family, psychiatric disorders, autism spectrum disorders, intellectual disability or learning difficulties, seizures or epilepsy, birth defects, recurrent pregnancy loss or stillbirth, autoimmune disorders, and other findings including additional multifactorial conditions and infant deaths. In close to half of the total consults, general risk counseling was provided, which added additional perspective to the reproductive or personal health risk information for the individual or couple. General risk counseling occurred most frequently for autoimmune disorders, which was discussed in 16.8% of the consults. Some of the major disorders most frequently discussed were diabetes, lupus, thyroid disorders, and multiple sclerosis. These results have implications for genetic counseling practices, particularly with regards to patient education. Such FHH findings provide opportunities for patient education by prompting discussion of co-genetic susceptibility. Psychiatric disorders prompted general risk counseling in approximately 10% of all consults, emerging as the second most frequently discussed topic. The most frequently discussed psychiatric disorders included depression, bipolar disorder, and schizophrenia. A positive family history is the greatest recognized risk factor for developing conditions such as schizophrenia and major depression (Laursen et al., 2005; Austin and Peay, 2006) . Although predictive genetic testing is currently not available for these conditions, the relevance of genetic counseling is not limited by the absence of testing (Jenkins & Arribas-Ayllon, 2016) . Past studies have found that providing patient education about etiology offer many benefits to affected individuals and their families (Austin & Honer, 2008; Hippman et al., 2013 Hippman et al., , 2016 . Patient education serves to improve knowledge, alleviate anxiety, and increase risk perception accuracy in those with heightened concern about their risk to develop a mental illness (2008; 2013; 2016) . The frequency with which psychiatric conditions came up in this study highlights the value of genetic counseling for individuals with positive family histories, who may benefit from patient education and counseling. For this study, general risk counseling for ASD was also provided in a little over 1% of all consults; a recurrence risk score was given as part of general risk counseling and was calculated based on the degree of relation of the family member affected with ASD. For these particular consults with positive family histories for ASD, it was determined that a recommendation for a genetics evaluation was not necessary but a discussion of reproductive risk was still warranted. Whether a family finding of ASD prompted a recommendation for further follow-up or general risk counseling was made at the genetic counselor's discretion. For all of these cases discussed, additional information and insight were gained through general risk counseling and patient education; however, this information did not prompt further actions or evaluations for the individual or couple.
The results of this study are subject to inherent limitations of the data. The inclusion criteria for the study restricted the population sample to individuals and couples that received expanded carrier screening through Recombine, thereby limiting the overall diversity of the patient population. Therefore, these results may only be applicable to genetic counseling consults that occur in context of an expanded carrier screening setting. Reported information was also subject to the genetic counselor's assessment of its importance and relevance to the consult. The information available through each consult's chart notes and consult letter may not reflect all the details of the consult. This limitation is compounded by the influence of counselor differences such as style, technique, and experience, all of which contribute to the specific information collected or recorded during a consult. For example, in some cases, recommendations were included in the consult letter irrespective of the finding's actual level of significance, relative reproductive risk to the individual or couple, or level of patient concern. Counselor discretion also played a role in whether a family history finding yielded a recommendation for follow-up or general risk counseling. Specific cases of this were observed in cases that involved recurrent pregnancy loss and autism spectrum disorder findings.
Only a small body of research exists on the clinical utility of FHH evaluations.
Overall, the results of this study provide insights into the type of information that can be elicited through a FHH evaluation. FHH provides supplemental information to the individual or couple's expanded carrier screening results, which adds to knowledge of personal health risk and reproductive risk. The frequency with which relevant findings were elicited during a family history evaluation also offers further support to its utility as a clinical tool in the patient-care setting. Family history studies can serve as a useful evaluation tool for nonroutine screening procedures, diagnostic testing, and referral to genetic counseling in different disciplines (Beadles et al., 2014) . Furthermore, FHH can be used as a screening tool to identify individuals who would benefit from further evaluation, additional risk counseling, or patient education. The results of this study provide support to the broader adoption of FHH evaluations in routine clinical care, which further warrants the use of genetic counselors in healthcare environments outside of traditional genetic settings (Wilson et al., 2012) . The implementation of thorough FHH as a routine clinical tool would enable better care and risk management for patients and their families (Brock et al., 2010; Tarini & McInerney, 2013; Wu et al., 2015) . FHH, however, remains an underutilized tool for risk assessment in primary care settings (Langlands, Prentice, & Ravine, 2010; Powell et al., 2013; Tarini & McInerney, 2013) . A number of studies have found that FHH data collected in primary care settings lacks the completeness needed to be used effectively as a risk assessment tool (Powell et al., 2013; Tarini & McInerney, 2013; B. J. Wilson et al., 2012) .
This further emphasizes the need for genetic counseling and genetics consultations to be performed by certified genetic professionals. Correct interpretation of FHH requires in-depth genetics knowledge that ensures accurate risk assessments, proper risk counseling, and appropriate recommendations for follow-up.
The study also provides perspective on patient's understanding and knowledge of their own FHH as well as insight into health topics that were of highest patient concern.
Further studies should look into how patients can prepare for a genetics consultation in order to obtain the most optimal outcome. A patient's knowledge of relevant FHH information Katherine Dao and Julia Russo 22/34 better enables healthcare professionals to personalize the care plan and management to a patient's risks and needs. From a provider's perspective, the results of this study elucidated on health topics and conditions that tend to come up more frequently than others during a FHH evaluation. This may then provide insight into the type of topics that can be expected to come up during a genetics consultation. Awareness and knowledge of these topics may be beneficial to genetic professionals as this can help facilitate risk assessment and counseling.
As medicine moves away from the "one size fits all model", the critical role of FHH in personalized medicine has become more apparent than ever. FHH is an easy and simple tool with high clinical utility that warrants its adoption into a variety of routine healthcare settings.
